Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention?

Journal of Alzheimer's Disease

Volumn 20, Issue 3, 2010, Pages 723-736

  Luchsinger, José A ^a,b,c,d  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NONE   (United States)

^d NONE   (United States)

Author keywords

Adiposity; Alzheimer's disease; cognitive impairment; glucose; hyperinsulinemia; insulin; obesity; overweight; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPONECTIN; AMYLOID BETA PROTEIN; BETA SECRETASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; INSULIN; INSULINASE; LEPTIN; LIPOPROTEIN; LIPOPROTEIN RELATED PROTEIN 1; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TAU PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ACIDOSIS; ADIPOSE TISSUE; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMENTIA; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EDEMA; EXERCISE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; GLYCOSYLATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LATE ONSET ALZHEIMER DISEASE; LEUKOARAIOSIS; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER AMEBIASIS; LOW FAT DIET; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PUBLIC HEALTH SERVICE; RETINA NEOVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENESCENCE; SIDE EFFECT; STROKE; TREATMENT OUTCOME; VASCULAR AMYLOIDOSIS; WHITE MATTER;

EID: 77954559472     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091687     Document Type: Review

References (167)

1. Ritchie K, Lovestone S (2002) The dementias. Lancet 360, 1759-1766.
2. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
3. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, ChownMJ, Hebert LE, Hennekens CH,Taylor JO (1989) Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 2551-2556.
4. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, Chang FL, Skinner K, Tasaki C, Jagust WJ (2000) Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol 57, 191-196.
5. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
6. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R (2003) Mild cognitive impairment: directions for future research. Neurology 61, 438-444.
7. Petersen RC, Smith GE,Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
8. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, the Alzheimer's Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388. (Pubitemid 40958434)
9. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC (2003) Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Br J Psychiatry 182, 449-454.
10. Yesavage JA, O'Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, Gely-Nargeot MC, Rosen A, Friedman L, Sheikh J, Derouesne C (2002) Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res 36, 281-286.
11. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM (2006) A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354, 2764-2772.
12. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347-1351.
13. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052.
14. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C,Westendorp RG, Risk PsgPSoPitEa (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630.
15. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
16. Centers for Disease Control and Prevention, Fact Sheet Press Release: Number of People with Diabetes Increases to 24 million, http://www.cdc.gov/ media/pressrel/2008/ r080624.htm, Accessed June 27.
17. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290, 1884-1890.
18. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76-79.
19. Freemantle N, Holmes J, Hockey A, Kumar S (2008) How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 62, 1391-1396.
20. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952.
21. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295, 1549-1555.
22. (2008) Standards of medical care in diabetes - 2008. Diabetes Care 31 Suppl 1, S12-54.
23. Brickman AM, Schupf N, Manly JJ, Luchsinger JA, Andrews H, Tang MX, Reitz C, Small SA, Mayeux R, DeCarli C, Brown TR (2008) Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol 65, 1053-1061.
24. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB, Sr. (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167, 1068-1074.
25. Florez H (2008) Diabetes risk engine with clinical variables. Int Diabetes Monitor 20, 119-120.
26. Reaven G (2005) Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation 112, 3030-3032.
27. DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37, 667-687.
28. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS (2000) Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23, 1278-1283.
29. Choi BC, Shi F (2001) Risk factors for diabetes mellitus by age and sex: results of the National Population Health Survey. Diabetologia 44, 1221-1231.
30. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345, 790-797.
31. Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: a lifespan perspective. Lancet Neurol 7, 184-190.
32. Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL (2008) Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care 31, 1132-1137.
33. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC (2003) Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke 34, 1586-1592.
34. Sacco RL (2002) Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes Metab 4 Suppl 1, S27-34.
35. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin I-F, Cheng JF, Paik MC, Shea S, Berglund L (2001) High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study. JAMA 285, 2729-2735. (Pubitemid 32525369)
36. Benson RT, Sacco RL (2000) Stroke prevention: hypertension, diabetes, tobacco, and lipids. Neurol Clin 18, 309-319.
37. Boden-Albala B, Sacco RL (2000) Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr Atheroscler Rep 2, 160-166.
38. Pi-Sunyer FX (2002) The Obesity Epidemic: Pathophysiology and Consequences of Obesity. Obes Res 10, 97S-104.
39. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP,Wolf PA (1997) American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 28, 1507-1517.
40. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: An American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752. (Pubitemid 41532612)
41. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3, 169-178.
42. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60, 1707-1712.
43. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-1222.
44. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
45. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204.
46. Arvanitakis Z, Schneider JA, Wilson RS, Li Y, Arnold SE, Wang Z, Bennett DA(2006) Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67, 1960-1965.
47. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
48. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66, 315-322.
49. Manschot SM, Brands AMA, van der Grond J, Kessels RPC, Algra A, Kappelle LJ, Biessels GJ, on behalf of the Utrecht Diabetic Encephalopathy StudyG(2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55, 1106-1113.
50. Pantoni L (2006) White matter ischemia: Time to begin integrating experimental and clinical data. Eur Neurol 56, 71-73.
51. Nakata-Kudo Y, Mizuno T, Yamada K, Shiga K, Yoshikawa K, Mori S, Nishimura T, Nakajima K, Nakagawa M (2006) Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 22, 8-14.
52. Haglund M, Englund E (2002) Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 14, 161-166.
53. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma {beta}-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29. (Pubitemid 43739586)
54. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM (1998) Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol 57, 353-359.
55. Park CR (2001) Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 25, 311-323.
56. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF A{beta}42 levels in normal older adults. Neurology 60, 1899-1903.
57. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105, 423-438.
58. Small SA, PereraGM,DeLaPaz R, Mayeux R, SternY(1999) Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 45, 466-472.
59. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
60. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152.
61. Banks WA, Jaspan JB, Huang W, Kastin AJ (1997) Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18, 1423-1429.
62. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24, 11120-11126.
63. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13, 950-958.
64. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
65. Reger MA, Watson GS, Frey WH, 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27, 451-458.
66. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597-605.
67. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63, 582-592. (Pubitemid 39078671)
68. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2007) Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85, 1236-1243.
69. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, SteffesM (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91, 11704-11708.
70. Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlassara H, Uribarri J (2006) Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT- 711). Am J Nephrol 26, 430-436.
71. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product crosslink breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53, 2921-2930.
72. Stitt AW (2001) Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 85, 746-753.
73. Schalkwijk CG, Lieuw-a-Fa M, van Hinsbergh VW, Stehouwer CD (2002) Pathophysiological role of Amadoriglycated proteins in diabetic microangiopathy. Semin Vasc Med 2, 191-197.
74. Sullivan KA, Feldman EL (2005) New developments in diabetic neuropathy. Curr Opin Neurol 18, 586-590.
75. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
76. Schmidt AM, Yan SD, Yan SF, SternDM(2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498, 99-111.
77. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171, 29-45.
78. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
79. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W,Wu Q, Sabo E, HovanesianV, StopaEG(2006)RAGE, LRP-1, and amyloidbeta protein in Alzheimer's disease. Acta Neuropathol (Berl) 112, 405-415.
80. Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72, 850-855.
81. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031.
82. Deane R,Wu Z, Sagare A, Davis J, Du Yan S, HammK, Xu F, Parisi M, LaRue B, HuHW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
83. Yu YH, Ginsberg HN (2005) Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 96, 1042-1052.
84. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, Decarli C, Wolf PA, Seshadri S (2009) Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302, 2565-2572.
85. Carro EM (2009) Therapeutic approaches of leptin in Alzheimer's disease. Recent Pat CNS Drug Discov 4, 200-208.
86. Kivipelto M, Ngandu T, Fratiglioni L,Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62, 1556-1560. (Pubitemid 41434560)
87. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330, 1360.
88. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71, 1057-1064.
89. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163, 1524-1528.
90. Stewart R, Masaki K, Xue Q-L, Peila R, Petrovitch H, White LR, Launer LJ (2005) A 32-year prospective study of change in body weight and incident dementia: The Honolulu-Asia Aging Study. Arch Neurol 62, 55-60.
91. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L (2008) Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc 56, 111-116.
92. Nourhashemi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P, Quid PsPA (2003) Body mass index and incidence of dementia: the PAQUID study. Neurology 60, 117-119.
93. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R (2007) Measures of adiposity and dementia risk in elderly persons. Arch Neurol 64, 392-398. (Pubitemid 46425695)
94. Stevens J, Cai J, Pamuk ER,Williamson DF, Thun MJ,Wood JL (1998) The effect of age on the association between bodymass index and mortality. N Engl J Med, 1-7.
95. Stevens J (2000) Impact of age on associations between weight and mortality. Nutr Rev 58, 129-137.
96. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, Jr., Luchsinger JA (2009) Midlife and latelife obesity and the risk of dementia: cardiovascular health study. Arch Neurol 66, 336-342.
97. Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH, Marder K, Albers MW, Stern Y, Devanand DP (2005) A 10- item smell identification scale related to risk for Alzheimer's disease. Ann Neurol 58, 155-160.
98. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, Bell K, Stern Y, Mayeux R (2000) Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry 157, 1399-1405.
99. Gustafson D (2008) A life course of adiposity and dementia. Eur J Pharmacol 585, 163-175.
100. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
101. Wedick NM, Mayer-Davis EJ, Wingard DL, Addy CL, Barrett-Connor E (2001) Insulin resistance precedes weight loss in adults without diabetes: The Rancho Bernardo Study. Am J Epidemiol 153, 1199-1205.
102. Razay G, Wilcock GK (1994) Hyperinsulinaemia and Alzheimer's disease. Age Ageing 23, 396-399.
103. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, LaaksoM(1997) Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315, 1045-1049.
104. Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts SW, Grobbee DE, Hofman A (1997) Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 20, 792-795.
105. Peila R, Rodriguez BL, White LR, Launer LJ (2004) Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63, 228-233.
106. Luchsinger JA, Tang M-X, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192.
107. Harris MI, Cowie CC, Gu K, Francis ME, Flegal K, Eberhardt MS (2002) Higher fasting insulin but lower fasting C-peptide levels in African Americans in the US population. Diabetes Metab Res Rev 18, 149-155.
108. Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F (2008) Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology 33, 455-461.
109. van Oijen M, Okereke OI, Kang JH, Pollak MN, Hu FB, Hankinson SE, Grodstein F (2008) Fasting insulin levels and cognitive decline in olderwomen without diabetes. Neuroepidemiology 30, 174-179.
110. Okereke O, Hankinson SE, Hu FB, Grodstein F (2005) Plasma C peptide level and cognitive function among older women without diabetes mellitus. Arch Intern Med 165, 1651-1656.
111. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett- Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63, 658-663.
112. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635-641.
113. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A, for the Italian Longitudinal Study on Aging Working Group (2004) Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63, 1882-1891.
114. MacKnight C, Rockwood K,Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14, 77-83. (Pubitemid 36152948)
115. Luchsinger JA, Reitz C, Patel B, Tang M-X, Manly JJ, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64, 570-575. (Pubitemid 46588347)
116. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, Vella A, Rocca WA, Petersen RC (2008) Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 65, 1066-1073.
117. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, Foley D, Blanchette PL, Harris T, Chen R, White LR (1999) Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 52, 971-975.
118. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E (2006) Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in olderwomen. J Nutr Health Aging 10, 293-295.
119. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292, 2237-2242.
120. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J (2006) Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 67, 843-847.
121. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA(2007) Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord 24, 185-192.
122. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551.
123. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, Ross GW, Havlik RJ, Launer LJ (2000) Metabolic cardiovascular syndrome and risk of dementia in Japanese- American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 20, 2255-2260.
124. Nathan DM, Berkwits M (2007) Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med 146, 461-463.
125. DeFronzo RA (2000) Pharmacologic therapy for type 2 diabetes mellitus. Ann Int Med 133, 73-74.
126. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research G (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 142, 611-619.
127. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344, 1343-1350. (Pubitemid 32378388)
128. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindstrom J, Tuomilehto J (2003) Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish diabetes prevention study. Diabetes 52, 2532-2538.
129. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen- Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673-1679. (Pubitemid 46048554)
130. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J (2005) Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev, CD005270.
131. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393-403.
132. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R,Venditti E, Nathan DM (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374, 1677-1686.
133. Colcombe S, Kramer AF (2003) Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci 14, 125-130. (Pubitemid 37283096)
134. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351, 1106-1118.
135. Nesto R (2004) C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 21, 810-817.
136. Cefalu WT (2009) Inflammation, insulin resistance, and type 2 diabetes: back to the future? Diabetes 58, 307-308.
137. Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37, 289-305.
138. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, ScherbaumW, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289.
139. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and AmericanDiabetes Association. Circulation 108, 2941-2948.
140. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355, 2427-2443.
141. Nissen SE,Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294, 2581-2586.
142. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356, 2457-2471.
143. Lincoff AM,Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180-1188.
144. Rabiner EA, Tzimopoulou S, Cunningham VJ, Jeter B, Zvartau-Hind M, Castiglia M, Mistry P, Bird NP, Matthews J, Whitcher B, Nichols TE, Lai R, Lotay N, Saunders A, Reiman E, Chen K, Gold M, Matthews PM (2009) Effects of 12 months of treatment with the PPAR? agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A 18F-FDG PET study. Alzheimers Dement 5, 207.
145. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334, 574-579.
146. Dunn CJ, Peters DH (1995) Metformin. A review of its pharmacological properties and therapeutic use in non-insulindependent diabetes mellitus. Drugs 49, 721-749.
147. Tian J, Shi J, Bailey K, Lendon CL, Pickering-Brown SM, Mann DMA (2004) Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75, 696-699. (Pubitemid 38526678)
148. The Diabetes Prevention Program Research G (2005) Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program: Effects of Lifestyle Intervention and Metformin. Diabetes 54, 2404-2414.
149. The Diabetes Prevention Program Research Group (2005) Intensive Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance. Diabetes 54, 1566-1572.
150. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research Group (2005) The effect
151. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393-403.
152. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via upregulating BACE1 transcription. Proc Natl Acad Sci U S A 106, 3907-3912.
153. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet 359, 2072-2077.
154. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ (2007) The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 99, 112i-122i.
155. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr., Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301, 1565-1572.
156. Shea S,Weinstock RS, Teresi JA, PalmasW, Starren J, Cimino JJ, Lai AM, Field L, Morin PC, Goland R, Izquierdo RE, Ebner S, Silver S, Petkova E, Kong J, Eimicke JP (2009) A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc 16, 446-456.
157. The Action to Control Cardiovascular Risk in Diabetes Study G (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358, 2545-2559.
158. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD (2005) Effects of Exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083-1091.
159. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145, 301-308. (Pubitemid 27082028)
160. Brayne C, Gill C, Huppert FA,BarkleyC, GehlhaarE, Girling DM, O'Connor DW, Paykel ES (1998) Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9, 175-180.
161. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
162. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61, 661-666.
163. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63, 1902-1907.
164. Xu WL, Qiu CX,Wahlin A,Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63, 1181-1186.
165. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281.
166. Xu W, Qiu C, Winblad B, Fratiglioni L (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56, 211-216.
167. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 65, 89-93.